Victory Capital Management
IBRX icon

Victory Capital Management’s ImmunityBio IBRX Stock Holding History

Victory Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
43,486
+724
+2% +$5.48K ﹤0.01% 2120
2026
Q1 		$328K Buy
42,762
+4,718
+12% +$32.3K ﹤0.01% 2111
2025
Q4 		$75.3K Buy
+38,044
New +$86.2K ﹤0.01% 2301
2025
Q2 		– Sell
-10,707
Closed -$32.2K – 2509
2025
Q1 		$32.2K Sell
10,707
-9,061
-46% -$27.5K ﹤0.01% 2397
2024
Q4 		$50.6K Buy
19,768
+8
+0% +$33 ﹤0.01% 2394
2024
Q3 		$73.5K Sell
19,760
-193
-1% -$893 ﹤0.01% 2356
2024
Q2 		$126K Buy
19,953
+2,746
+16% +$18.1K ﹤0.01% 2267
2024
Q1 		$92.4K Sell
17,207
-435
-2% -$1.97K ﹤0.01% 2314
2023
Q4 		$88.6K Buy
17,642
+3,613
+26% +$11.3K ﹤0.01% 2365
2023
Q3 		$23.7K Buy
+14,029
New +$28.2K ﹤0.01% 2438
2022
Q3 		– Sell
-11,741
Closed -$44K – 2731
2022
Q2 		$44K Sell
11,741
-75
-0.6% -$301 ﹤0.01% 2561
2022
Q1 		$43K Buy
11,816
+248
+2% +$1.52K ﹤0.01% 2607
2021
Q4 		$70K Sell
11,568
-13,890
-55% -$104K ﹤0.01% 2621
2021
Q3 		$248K Buy
25,458
+1,033
+4% +$11.4K ﹤0.01% 2446
2021
Q2 		$349K Sell
24,425
-11,228
-31% -$185K ﹤0.01% 2363
2021
Q1 		$846K Buy
35,653
+4,098
+13% +$106K ﹤0.01% 1982
2020
Q4 		$421K Buy
+31,555
New +$304K ﹤0.01% 2157
2020
Q2 		– Sell
-5,623
Closed -$16K – 2849
2020
Q1 		$16K Buy
+5,623
New +$28.2K ﹤0.01% 2920
2019
Q4 		– Sell
-9,415
Closed -$11K – 2916
2019
Q3 		$11K Buy
+9,415
New +$11.7K ﹤0.01% 3227

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management's IBRX Position: Q2 2026 in Review

Victory Capital Management increased its ImmunityBio (IBRX) stake by 1.7% in Q2 2026, buying an estimated $5.48K and bringing the position to 43,486 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #2120.

Victory Capital Management first reported a position in IBRX in Q3 2019 and has held it in 19 quarters since. The position peaked at $846K in Q1 2021. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Victory Capital Management held 43,486 shares of ImmunityBio worth $381K as of Q2 2026.
  • Victory Capital Management bought 724 ImmunityBio shares in Q2 2026, an estimated $5.48K.
  • ImmunityBio made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2120 holding.
  • Victory Capital Management first reported a position in ImmunityBio in Q3 2019 and has held it in 19 quarters since.
  • Victory Capital Management's ImmunityBio position peaked at $846K in Q1 2021.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.